DermACELL: Human Acellular Dermal Matrix Allograft

2016 ◽  
Vol 106 (2) ◽  
pp. 133-137 ◽  
Author(s):  
Windy E. Cole

Diabetes often causes ulcers on the feet of diabetic patients. A 56-year-old, insulin-dependent, diabetic woman presented to the wound care center with a Wagner grade 3 ulcer of the right heel. She reported a 3-week history of ulceration with moderate drainage and odor and had a history of ulceration and osteomyelitis in the contralateral limb. Rigorous wound care, including hospitalization; surgical incision and drainage; intravenous antibiotic drug therapy; vacuum-assisted therapy; and a new room temperature, sterile, human acellular dermal matrix graft were used to heal the wound, save her limb, and restore her activities of daily living. This case presentation involves alternative treatment of a diabetic foot ulcer with this new acellular dermal matrix, DermACELL.

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Gianluca Franceschini ◽  
Riccardo Masetti

AbstractAcellular dermal matrices are biological materials of porcine, bovine, or human origin used as scaffold for reconstructive purpose in plastic surgery; these materials are well-tolerated and safely integrated in host tissues without causing resorption, contracture, and encapsulation thanks to their low antigenicity.Recently, human acellular dermal matrix has been used as a filler in breast-conserving surgery to improve aesthetic results. Adequate knowledge of biomaterials properties, appropriate skill, and careful compliance with some specific recommendations are mandatory in order to optimize outcomes and obtain a work of success.


2019 ◽  
Vol 85 (9) ◽  
pp. 1056-1060
Author(s):  
Rachel E. Lewis ◽  
Emily A. Towery ◽  
Sneha G. Bhat ◽  
Andrew J. Ward ◽  
Robert E. Heidel ◽  
...  

Skin substitutes have shown success in complex wound reconstruction. We evaluate the use of a human acellular dermal matrix (ADM) as a viable alternative to autologous skin grafting for defects secondary to skin cancer excision. An institutional review board–approved, retrospective review of ADM-reconstructed defects secondary to skin cancer excision between 2012 and 2018 was conducted. ADM was indicated in patients with preclusive factors for general anesthesia, protracted procedure time, reluctance for additional donor site wound, and personal choice. We reviewed defect characteristics, healing time, postoperative outcomes, and patient demographics. The 228 participants (151 males, 77 females) had a median age of 72 years (range, 29–95 years), with melanoma diagnosed in 113 (49.6%), squamous cell carcinoma in 61 (26.8%), and basal cell carcinoma in 28 (12.2%) patients. The median interval to complete epidermal coverage was 42 days, with graft failure evident in six patients (2.6%). ADM is a viable, low-morbid alternative for reconstruction of defects secondary to skin cancer excision, with no donor site morbidity. With exception to complete healing time, outcomes are similar to those of autologous grafting.


2008 ◽  
Vol 60 (1) ◽  
pp. 76-80 ◽  
Author(s):  
Rachel Bluebond-Langner ◽  
Emily S. Keifa ◽  
Suhail Mithani ◽  
Grant V. Bochicchio ◽  
Thomas Scalea ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document